SABITALKS / KDM2B in Breast Cancer: Epigenetic Mechanisms and Therapeutic Vulnerabilities
Dr. Burak Soysal from The Ohio State University is going to be at SABITALKS on August 22, 2025 at 14:00. The event will take place in person.
Location: Istanbul Medipol University North Campus / Building C, C-Z09
https://goo.gl/maps/JDDjygVtFLWiPiMJA
*Participants from outside SABITA must fill in the participation form.
KDM2B in Breast Cancer: Epigenetic Mechanisms and Therapeutic Vulnerabilities
AI-enabled targeting of KDM2B, a JmjC histone demethylase that will become a synthetic lethal dependency in BRCA1-mutant breast cancer, will be discussed. A short primer on KDM2B biology will be presented, then it will be shown how BRCA1 loss will upregulate KDM2B networks. Using CRISPRi/Rescue and single-cell/long-read multi-omics, the regulators and metabolic/RNA vulnerabilities that KDM2B controls will be mapped.
Dr. Burak Soysal
The Ohio State University
I’m currently a postdoctoral fellow at The Ohio State University Comprehensive Cancer Center. My academic journey began with an MD degree from Erciyes University in Turkey, where I also practiced as a physician before fully transitioning into research. That clinical background continues to shape how I think about scientific problems with a strong focus on how discoveries can eventually reach patients.
My current research centers on epigenetic vulnerabilities in breast cancer, particularly the role of KDM2B in BRCA1-deficient tumors. I use a combination of molecular biology techniques such as CRISPR, RNA-seq, ribosome profiling and AI-driven computational tools to uncover mechanisms that might open new therapeutic avenues.
Beyond the bench, I’ve had the opportunity to mentor students, collaborate across disciplines, and recently started exploring how genome-editing technologies could intersect with cancer biology an area I’m especially excited about moving forward.